ResearcherSecond Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Jianbing Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4576-7286; OpenAlex author ID A5027797567. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer. Co-author DOI 10.1007/s10238-026-02201-8 ↗
MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2. Last author DOI 10.18632/aging.205320 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

M Y Li · 1 shared paper, 2026 · strength 0.36
- Paper Current advances in immunotherapy for KRAS-Mutant pancreatic cancer. DOI 10.1007/s10238-026-02201-8 ↗
Ye Mao · 1 shared paper, 2026 · strength 0.36
- Paper Current advances in immunotherapy for KRAS-Mutant pancreatic cancer. DOI 10.1007/s10238-026-02201-8 ↗
Chen Huan Luo · 1 shared paper, 2023 · strength 0.20
- Paper MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2. DOI 10.18632/aging.205320 ↗
Dan Li · 1 shared paper, 2023 · strength 0.20
- Paper MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2. DOI 10.18632/aging.205320 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.